Ascletis Pharma Appoints CFO

Dr. Lindi Tan has been appointed chief financial officer, Ascletis Pharma Inc., a commercial-stage biopharma company focused on therapeutic areas including anti-viral, cancer and fatty liver diseases.

Dr. Tan is a healthcare professional with extensive knowledge in the biotech sector. Prior to joining Ascletis, Dr. Tan held roles at SeaTown Holdings International and Temasek International. Dr. Tan was the global healthcare analyst at SeaTown and was responsible for driving multi-asset investments. At Temasek International, she held an investment role in the Life Sciences team and was the Staff Officer to the Chief Investment Officers/Heads of Investments.
"We are very pleased to welcome Lindi to the management team," said Jinzi J. Wu, PhD., Founder, chairman and chief executive officer of Ascletis. "She brings to Ascletis more than 15 years of investment, finance, research and management experience in the global healthcare sector and has a proven track record of healthcare investing and partnering. Her extensive experience, leadership, and familiarity with our business makes her an ideal choice to help lead Ascletis as we move on to the next phase of our transformation."

-------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.